cipla

Looking at continued growth across key markets in FY20: Cipla

Cipla posted a net profit of Rs 1,492.44 crore for the 2018-19 fiscal as against Rs 1,416.57 crore in 2017-18.

Cipla banks on limited competition launches to drive growth in US

The company said it’s planning to launch at least one limited competition drug every month.

Cipla Consolidated March 2019 Net Sales at Rs 4,403.98 crore, up 19.09% Y-o-Y

Cipla Standalone March 2019 Net Sales at Rs 3,456.53 crore, up 26.83% Y-o-Y

Cipla Q4 net profit jumps 133% at Rs 357.68 crore

The company board has approved raising up to Rs 6,000 crore

USFDA inspection at Indore facility ends with zero observations: Cipla

'We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations,' the company said in a BSE filing.

Cash Market | A good risk reward trade in Cipla

Cipla has taken support on a support line and the pitchfork. The stock can move higher from current level offering a good risk reward trade

'Short-term traders can sell Nifty below 11,630 with stop loss at 11,700'

Contra traders should look for short selling opportunity around 11,750/11,760 with a final stop loss at 11,810

Cipla gets USFDA nod for pulmonary arterial hypertension drug

Cipla's Ambrisentan tablets 5 mg and 10 mg is AB-rated generic therapeutic equivalent version of Gilead Sciences Inc's Letairis.

Dr Reddy's Laboratories, Cipla arm recall drugs in US market

Dr Reddy's Laboratories Inc, a subsidiary of the Hyderabad-based Dr Reddy's Laboratories, is voluntarily recalling the affected lot of bottles on account of certain deviations from the Current Good Manufacturing Practice (CGMP) regulations.

Cipla Q4 PAT seen up 93.2% YoY to Rs. 295.8 cr: Kotak

Net Sales are expected to increase by 7.3 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 3,969.1 crore, according to Kotak.

Cipla, Pulmatrix join hands to co-develop asthma drug

Pulmazole an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, it added.

Cipla Q4 PAT seen up 58.5% YoY to Rs. 283.1 cr: Prabhudas Lilladher

Net Sales are expected to increase by 9.5 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,829.1 crore, according to Prabhudas Lilladher.

Cipla launches Niveoli inhaler in India

Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing.

D-Street Buzz: Realty stocks shine led by Indiabulls Real Estate; Cipla jumps 2%, HDFC Bank most active

The top Nifty gainers include Cipla, Indiabulls Housing Finance, ONGC, Zee Entertainment and Kotak Mahindra Bank while TCS, Hindalco Industries, HCL Tech, Hero MotoCorp and HDFC are the top losers.

D-Street Buzz: Tata Steel, Cipla jump 3% each; DHFL extends gains, SBI drags

The top Nifty gainers include Tata Steel, Cipla, Eicher Motors, UltraTech Cement and Vedanta while State Bank of India, Power Grid, Britannia Industries, Tata Motors and Zee Entertainment are the top losers.

Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug

Pulmazole is an inhaled anti-fungal formulation of itraconazole aimed at treating allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.

Cipla falls 2% on 8 GMP observations for Kurkumbh plant

These observations are both product specific and GMP observations related to the manufacturing and quality processes, Cipla said

Cipla gets 8 GMP observations from USFDA for Kurkumbh plant

The USFDA inspection covered 3 units at Kurkumbh plant.

Comment | Cipla takes a calculated risk with generic Sensipar launch

Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk

India requires pragmatic compulsive licensing system: Cipla

The industry doyen pointed out that 70 percent of the major drugs are in-licensed and it is what India should look to do.

Cipla to launch cinacalcet hydrochloride tablets in US

Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.

Cipla to acquire 11.71% stake in Wellthy Therapeutics

Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands.

Buy Cipla; target of Rs 605: HDFC Securities

HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 605 in its research report dated February 07, 2019.

Hold Cipla; target of Rs 545: ICICI Direct

ICICI Direct recommended hold rating on Cipla with a target price of Rs 545 in its research report dated February 07, 2019.